See why Dr. Pimentel, Dr. Brenner, and Joscelyn Greaves, MSN, APRN-CNP, think XIFAXAN FIRST

Mark Pimentel, MD

Executive Director, Medically Associated Science and Technology Program
Cedars-Sinai Medical Center

Darren Brenner, MD

Associate Professor of Medicine and Surgery
Director, Neurogastromotility and Functional Bowel Programs
Director, Motts Tonelli GI Physiology Laboratory
Northwestern University Feinberg School of Medicine

Joscelyn Greaves, MSN, APRN-CNP

Gastroenterology Specialists, Inc.


Watch Dr. Pimentel, Dr. Brenner, and Joscelyn Greaves, MSN, APRN-CNP, discuss why they think XIFAXAN FIRST for their adult patients with IBS-D.

IBS-D = irritable bowel syndrome with diarrhea


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.